Logo image of GBS

GBS INC (GBS) Stock Fundamental Analysis

NASDAQ:GBS - Nasdaq - US36151G1058 - Common Stock - Currency: USD

0.4732  0 (-0.04%)

After market: 0.48 +0.01 (+1.44%)

Fundamental Rating

2

GBS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of GBS is average, but there are quite some concerns on its profitability. GBS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GBS has reported negative net income.
In the past year GBS has reported a negative cash flow from operations.
In the past 5 years GBS always reported negative net income.
GBS had a negative operating cash flow in each of the past 5 years.
GBS Yearly Net Income VS EBIT VS OCF VS FCFGBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

Industry RankSector Rank
ROA -67.24%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GBS Yearly ROA, ROE, ROICGBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 500 1K 1.5K 2K 2.5K

1.3 Margins

Industry RankSector Rank
OM -1907.1%
PM (TTM) -1900.05%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GBS Yearly Profit, Operating, Gross MarginsGBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, GBS has more shares outstanding
There is no outstanding debt for GBS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GBS Yearly Shares OutstandingGBS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 5M 10M
GBS Yearly Total Debt VS Total AssetsGBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -4.38, we must say that GBS is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for GBS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.38
ROIC/WACCN/A
WACCN/A
GBS Yearly LT Debt VS Equity VS FCFGBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 5M -5M 10M -10M 15M

2.3 Liquidity

A Current Ratio of 2.33 indicates that GBS has no problem at all paying its short term obligations.
A Quick Ratio of 2.33 indicates that GBS has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.33
Quick Ratio 2.33
GBS Yearly Current Assets VS Current LiabilitesGBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

GBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.84%, which is quite good.
GBS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -77.90%.
EPS 1Y (TTM)17.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.11%
Revenue 1Y (TTM)-77.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-95.84%

3.2 Future

The Earnings Per Share is expected to grow by 12.02% on average over the next years. This is quite good.
Based on estimates for the next years, GBS will show a very strong growth in Revenue. The Revenue will grow by 160.02% on average per year.
EPS Next Y44.09%
EPS Next 2Y35.56%
EPS Next 3Y20.24%
EPS Next 5Y12.02%
Revenue Next Year-100%
Revenue Next 2Y547.11%
Revenue Next 3Y251.78%
Revenue Next 5Y160.02%

3.3 Evolution

GBS Yearly Revenue VS EstimatesGBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2024 2025 2026 5M 10M 15M
GBS Yearly EPS VS EstimatesGBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GBS. In the last year negative earnings were reported.
Also next year GBS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GBS Price Earnings VS Forward Price EarningsGBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GBS Per share dataGBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

GBS's earnings are expected to grow with 20.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.56%
EPS Next 3Y20.24%

More info and screens

0

5. Dividend

5.1 Amount

GBS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GBS INC

NASDAQ:GBS (10/26/2022, 8:00:00 PM)

After market: 0.48 +0.01 (+1.44%)

0.4732

0 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-31 2022-08-31/amc
Earnings (Next)11-10 2022-11-10/bmo
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.15%
Ins Owner Change0%
Market Cap7.05M
Analysts0
Price Target4.59 (869.99%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.12
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.03
BVpS0.44
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.24%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -1907.1%
PM (TTM) -1900.05%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.33
Quick Ratio 2.33
Altman-Z -4.38
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.11%
EPS Next Y44.09%
EPS Next 2Y35.56%
EPS Next 3Y20.24%
EPS Next 5Y12.02%
Revenue 1Y (TTM)-77.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-95.84%
Revenue Next Year-100%
Revenue Next 2Y547.11%
Revenue Next 3Y251.78%
Revenue Next 5Y160.02%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.27%
OCF growth 3YN/A
OCF growth 5YN/A